Vitae's Vagueness On Psoriasis Program Spooks Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision to end enrollment prematurely of Phase IIa proof-of-concept study apparently has led investors to assume safety issues for the first-in-class ROR gamma T inhibitor.
You may also be interested in...
Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?
Allergan’s $639m purchase of Vitae Pharmaceuticals gives the company an oral drug for a key dermatology indication and the potential to address other autoimmune disorders consistent with its focus on seven key therapeutic areas.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.